Results 101 to 110 of about 235,116 (346)
Pancreatic tumors imaging: an update [PDF]
, 2016 Currently, ultrasound (US), computed tomography (CT) and Magnetic Resonance imaging (MRI) represent the mainstay in the evaluation of pancreatic solid and cystic tumors affecting pancreas in 80-85% and 10-15% of the cases respectively. Integration of US,
Baccari, Paolo +8 more
core +1 more source
International Journal on Biological Sciences, 2018 Since the five-year survival rate is less than 5%, pancreatic ductal adenocarcinoma (PDAC) remains the 4th cause of cancer-related death. Although PDAC has been repeatedly researched in recent years, it is still predicted to be the second leading cause ...
Zhou Zhou +6 more
semanticscholar +1 more source
Advanced Science, EarlyView.This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia +6 more
wiley +1 more source
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy [PDF]
, 2017 Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the identification of novel targets and development of effective treatment strategies are urgently needed to improve patient outcomes.
Olson, Michael F. +4 more
core +1 more source
TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
Advanced Science, EarlyView.We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng +9 more
wiley +1 more source
Case Reports in Gastroenterology, 2018 The natural growth rate of pancreatic carcinoma in situ with pancreatic duct stricture remains unclear. Herein, we present a case with pancreatic duct stricture that rapidly grew to form a mass lesion within 3 months.
Shin Kato +3 more
doaj +1 more source
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. [PDF]
, 2014 BackgroundPancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have ...
Bold, Richard J +3 more
core +2 more sources
NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma
Journal of Experimental Medicine, 2017 The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance, which enables disease to progress unabated by adaptive immunity.
Donnele Daley +21 more
semanticscholar +1 more source
Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma [PDF]
Cancer Science, 2003 Pancreatic ductal carcinoma (PDC) is one of the most intractable human malignancies. Surgical resection of PDC at curable stages is hampered by a lack of sensitive and reliable detection methods. Given that DNA microarray analysis allows the expression of thousands of genes to be monitored simultaneously, it offers a potentially suitable approach to ...
Koji, Yoshida +14 more
openaire +2 more sources
Advanced Science, EarlyView.Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao +14 more
wiley +1 more source